Repositorio Dspace

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

Mostrar el registro sencillo del ítem

dc.contributor.author Franco-Pérez, Fernando
dc.contributor.author Lavernia, Javier
dc.contributor.author Aguiar-Bujanda, David
dc.contributor.author Miramon, Jose
dc.contributor.author Guma, Josep
dc.contributor.author Álvarez, Rut
dc.contributor.author Gómez-Codina, Jose
dc.contributor.author García-Arroyo, Francisco
dc.contributor.author Llanos, Marta
dc.contributor.author Marín-Vera, Miguel
dc.contributor.author Alfaro, Jesús
dc.contributor.author Quero, Cristina
dc.contributor.author Delgado, Mayte
dc.contributor.author Nogales, Esteban
dc.contributor.author Menarguez, Francisco
dc.contributor.author Martínez, Natividad
dc.contributor.author Torrente, María
dc.contributor.author Royuela, Ana
dc.contributor.author Abreu, Delvys
dc.contributor.author Provencio, Mariano
dc.date.accessioned 2026-02-12T12:02:41Z
dc.date.available 2026-02-12T12:02:41Z
dc.date.issued 2017-03
dc.identifier.citation Franco Pérez F, Lavernia J, Aguiar-Bujanda D, Miramón J, Gumá J, Álvarez R, et al. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. Clinical Lymphoma Myeloma and Leukemia. marzo de 2017;17(3):186-91.
dc.identifier.issn 2152-2650
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/24147
dc.description.abstract INTRODUCTION: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. MATERIALS AND METHODS: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. RESULTS: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. CONCLUSION: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.
dc.language.iso eng
dc.publisher CIG MEDIA GROUP, LP
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ *
dc.subject.mesh Adult
dc.subject.mesh Aged
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Antineoplastic Agents/therapeutic use
dc.subject.mesh Breast Neoplasms/drug therapy/mortality/pathology
dc.subject.mesh Breast Neoplasms, Male/drug therapy/mortality/pathology
dc.subject.mesh Disease-Free Survival
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Lymph Nodes/pathology
dc.subject.mesh Lymphoma/drug therapy/mortality/pathology
dc.subject.mesh Lymphoma, Non-Hodgkin/drug therapy/mortality
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Prognosis
dc.subject.mesh Treatment Outcome
dc.title Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 27847267
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S2152265016305602
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.clml.2016.09.004
dc.journal.title Clinical Lymphoma Myeloma & Leukemia
dc.identifier.essn 2152-2669


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta